Charles University, Czech Republic
cuni.czLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
221
Active
64
Phase 3
9
Total enrollment
53,068
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Oroxid® | — | — | — | — | — | 1 | |
| Chlorhexidine mouthwash | — | — | — | — | — | 1 | |
| Sevoflurane | — | — | — | — | — | 1 | |
| Cyteal | — | — | — | — | — | 1 | |
| Acipimox | — | — | — | — | — | 1 | |
| Isoflurane Inhalational Sedation | — | — | — | — | — | 1 |
Next readouts
- 2007-12-16
- 2025-06
- 2026-04-30
- 2029-12-31
Top conditions
- Atrial Fibrillation15
- Motor Activity8
- Multiple Sclerosis8
- Diabetes Mellitus, Type 15
- Pelvic Organ Prolapse4
- Atrial Fibrillation (AF)4
- Critical Illness4
- Rehabilitation4
Frequently asked questions about Charles University, Czech Republic
- How many clinical trials does Charles University, Czech Republic have on ClinicalTrials.gov?
- Charles University, Czech Republic is listed as the lead sponsor on 221 clinical trials in ClinicalTrials.gov, 64 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Charles University, Czech Republic's trials are in Phase 3?
- 9 of Charles University, Czech Republic's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does Charles University, Czech Republic focus on?
- Charles University, Czech Republic's most-studied conditions on ClinicalTrials.gov are Atrial Fibrillation, Motor Activity, Multiple Sclerosis, Diabetes Mellitus, Type 1, Pelvic Organ Prolapse.
- When are Charles University, Czech Republic's next clinical trial readouts?
- Charles University, Czech Republic has 4 upcoming primary-completion readouts tracked here; the soonest is “Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia”, expected around 2007-12-16.